Clinical Trial Update: Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31-7164) in Healthy Adults [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety and immune response of the dengue vaccine candidate rDEN3delta30/31-7164 in healthy adults; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue Fever

Drugs mentioned

• rDEN3delta30/31-7164

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Dengue Fever | Phase 1 | Status: COMPLETED